Status:

NOT_YET_RECRUITING

NG101m Adjuvant Therapy in Glioblastoma Patients

Lead Sponsor:

NeuGATE Theranostics

Conditions:

Glioblastoma Multiforme

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with...

Detailed Description

Glioblastoma multiforme (GBM) is the most lethal form of malignant brain cancer, with about 12,000 new cases diagnosed each in the the United States. The current standard treatment consists of maximal...

Eligibility Criteria

Inclusion

  • Male or female subjects ≥ 18 years of age
  • Must be newly diagnosed with GBM
  • Primary treatment must consist of a chemoradiation therapy (CRT) regimen
  • Hemoglobin \> 9 g/dL
  • White blood count 3,600 - 11,000/mm3
  • Absolute neutrophil count (ANC) ≥ 1,500/mm3
  • Absolute lymphocyte count (ALC) ≥ 1,000/mm3
  • Platelet count 100,000/mm3
  • BUN ≤ 1.5 times upper limit of normal
  • Creatinine clearance rate \> 40 mL/min
  • ALT ≤ 3 times upper limit of normal
  • AST ≤ 3 times upper limit of normal
  • Alkaline phosphatase ≤ 3 times upper limit of normal
  • Total bilirubin ≤ 2.0 mg/dL
  • Karnofsky Performance Status ≥ 70
  • Must not be on any other alternative therapies
  • Not pregnant

Exclusion

  • Known hypersensitivity to meloxicam, famotidine, and/or caffeine or any of their derivatives or components
  • Known allergy to vitamin A, vitamin D3, and/or L-citrulline
  • Pregnant women
  • Breastfeeding women
  • Corticosteroid therapy that cannot be tapered down to a dose of 1 - 2 mg/day of dexamethasone or its equivalent
  • History of immunodeficiency diseases or autoimmune diseases
  • History of peptic ulcer disease or gastrointestinal perforation

Key Trial Info

Start Date :

January 1 2027

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2030

Estimated Enrollment :

52 Patients enrolled

Trial Details

Trial ID

NCT04373785

Start Date

January 1 2027

End Date

December 31 2030

Last Update

October 21 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Yvonne Kew MD, PLLC

Houston, Texas, United States, 77030